Study of Olaparib in Ovarian Cancer

Trial setting: **Platinum Sensitive Relapsed High grade serous ovarian cancer with a BRCA mutation or high grade endometrioid cancer**

Study Design: **A Phase III, Randomised, Double Blind, Placebo Controlled**

Sponsor(s): **AstraZeneca**

Final No. of patients: **295**


Publications: **In submission**

Planned publications and substudies:

To be discussed at the SOLO-2 TSC meeting (June 3rd 6:30 am)
Primary Endpoint presented at SGO on March 2017

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the Phase III SOLO2 study

Eric Pujade-Lauraine,1 Jonathan A Ledermann,2 Richard T Penson,3 Amit M Oza,4 Jacob Korach,5 Tomasz Huzarski,6 Andrés Poveda,7 Sandro Pignata,8 Michael Friedlander,9 and Nicoletta Colombo10

Funded by AstraZeneca; ClinicalTrials.gov number NCT01874353

1Université Paris Descartes, AP-HP, Paris, France; 2University College London, London, UK; 3Massachusetts General Hospital and Harvard University, Boston, USA; 4Princess Margaret Cancer Centre, Toronto, Canada; 5Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel; 6Pomeranian Medical University, Szczecin, Poland; 7Instituto Valenciano de Oncologia, Valencia, Spain; 8Istituto Tumori Pascale di Napoli, Naples, Italy; 9University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, Australia; 10University of Milan-Bicocca and Istituto Europeo Oncologia (IEO), Milan, Italy
Tomorrow, do not miss ....

• M. Friedlander Oral presentation on QOL data
• Poster discussion on Tolerability